Business Context and Reporting Period
This Form 6-K filing by Biodexa Pharmaceuticals Plc covers the month of January 2026, with a filing date of January 6, 2026. The report details a significant change in executive leadership and board composition.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance data.
Material Changes
- Executive Appointment: Fiona Sharp was appointed as Chief Financial Officer (CFO), Corporate Secretary, and a member of the Board of Directors, effective January 5, 2026.
- Role Transition: Stephen Stamp relinquished his positions as CFO and Corporate Secretary but remains as Chief Executive Officer (CEO).
- Board Term: Ms. Sharp's directorship term is set to expire at the Company's annual general meeting in 2026.
Management Commentary and Risks
Ms. Sharp brings extensive financial experience, having served as the Company's Group Financial Controller since December 2019. Prior to joining Biodexa, she held financial leadership roles at Chime Communications Limited and the Hywell DDA University Health Board. She is a Chartered Certified Accountant. The filing states there are no family relationships between Ms. Sharp and other directors, no undisclosed arrangements regarding her selection, and no reportable transactions between her and the Company.
Investor Verification Checklist
- Confirm the effective date of Fiona Sharp's new roles (January 5, 2026).
- Verify Stephen Stamp's continued tenure as CEO following his departure from the CFO role.
- Review Ms. Sharp's prior experience as Group Financial Controller within the company since 2019.
- Note that no financial performance data is included in this specific filing.